Pituitary adenylate cyclase‐activating polypeptide prevents contrast‐induced nephropathy in a novel mouse model

We determined whether pituitary adenylate cyclase‐activating polypeptide 38 (PACAP38) prevents contrast‐induced nephropathy using human renal proximal tubule epithelial (HK‐2) cells and homozygous endothelial nitric oxide synthase‐deficient (eNOS−/−) mice as a novel in vivo model. Cultured HK‐2 cells were pretreated with 10−9–10−6 mol/L PACAP or vasoactive intestinal peptide (VIP) for 1 h, and then exposed to ionic (Urografin) or nonionic (iohexol) contrast media at 50 mg iodine/mL for 24 h. Male eNOS−/− mice received Urografin (1.85 g iodine/kg) intravenously after water deprivation for 24 h, and PACAP38 (10 μg) intraperitoneally 1 h before and 12 h after Urografin injection. Urografin and iohexol increased lactate dehydrogenase and kidney injury molecule 1 in the culture medium, induced apoptosis, and inhibited cell proliferation in HK‐2 cell cultures. PACAP38 and VIP reduced these changes in a dose‐dependent manner. PACAP38 was more potent than VIP. In eNOS−/− mice, Urografin raised serum creatinine and cystatin C levels, caused renal tubule damage, induced apoptosis, and promoted neutrophil influx. Urografin also increased kidney protein levels of proinflammatory cytokines, and kidney mRNA levels of proinflammatory cytokines, kidney injury biomarkers, and enzymes responsible for reactive oxygen and nitrogen species. PACAP38 significantly reduced these Urografin‐induced changes in eNOS−/− mice. This study shows that both Urografin and iohexol are toxic to HK‐2 cells, but Urografin is more toxic than iohexol. Urografin causes acute kidney injury in eNOS−/− mice. PACAP38 protects HK‐2 cells and mouse kidneys from contrast media and is a potential therapeutic agent for contrast‐induced nephropathy. e00163 Pituitary adenylate cyclase‐activating polypeptide (PACAP38) protects HK‐2 cells against the toxicity caused by ionic and nonionic contrast media. PACAP38 protects the structure and function of the kidney in endothelial nitric oxide synthase (eNOS)‐deficient mice against the deleterious effects of the ionic contrast medium Urografin. PACAP38 is a potential therapeutic agent to prevent contrast‐induced nephropathy.